Aura Biosciences (AURA) Competitors $6.59 +0.13 (+2.01%) As of 07/3/2025 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AURA vs. CALT, DYN, AMPH, NAGE, AUPH, ELVN, ABCL, WVE, VERV, and PAHCShould you be buying Aura Biosciences stock or one of its competitors? The main competitors of Aura Biosciences include Calliditas Therapeutics AB (publ) (CALT), Dyne Therapeutics (DYN), Amphastar Pharmaceuticals (AMPH), Niagen Bioscience (NAGE), Aurinia Pharmaceuticals (AUPH), Enliven Therapeutics (ELVN), AbCellera Biologics (ABCL), WAVE Life Sciences (WVE), Verve Therapeutics (VERV), and Phibro Animal Health (PAHC). These companies are all part of the "pharmaceutical products" industry. Aura Biosciences vs. Its Competitors Calliditas Therapeutics AB (publ) Dyne Therapeutics Amphastar Pharmaceuticals Niagen Bioscience Aurinia Pharmaceuticals Enliven Therapeutics AbCellera Biologics WAVE Life Sciences Verve Therapeutics Phibro Animal Health Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Aura Biosciences (NASDAQ:AURA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings and profitability. Is CALT or AURA more profitable? Aura Biosciences has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Aura Biosciences' return on equity of -58.63% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Calliditas Therapeutics AB (publ)-30.18% -212.04% -27.96% Aura Biosciences N/A -58.63%-49.74% Do insiders & institutionals have more ownership in CALT or AURA? 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by insiders. Comparatively, 5.4% of Aura Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more risk and volatility, CALT or AURA? Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500. Comparatively, Aura Biosciences has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500. Which has better earnings & valuation, CALT or AURA? Calliditas Therapeutics AB (publ) has higher revenue and earnings than Aura Biosciences. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62Aura BiosciencesN/AN/A-$86.92M-$1.90-3.47 Do analysts recommend CALT or AURA? Aura Biosciences has a consensus target price of $22.00, indicating a potential upside of 233.84%. Given Aura Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Aura Biosciences is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Aura Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25 Does the media refer more to CALT or AURA? In the previous week, Aura Biosciences had 1 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 1 mentions for Aura Biosciences and 0 mentions for Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ)'s average media sentiment score of 0.00 equaled Aura Biosciences'average media sentiment score. Company Overall Sentiment Calliditas Therapeutics AB (publ) Neutral Aura Biosciences Neutral SummaryAura Biosciences beats Calliditas Therapeutics AB (publ) on 10 of the 15 factors compared between the two stocks. Get Aura Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AURA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AURA vs. The Competition Export to ExcelMetricAura BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$329.76M$2.91B$5.53B$9.05BDividend YieldN/A2.44%5.24%4.03%P/E Ratio-3.4721.5627.5220.22Price / SalesN/A281.76421.02118.64Price / CashN/A42.7336.8958.07Price / Book2.177.518.045.67Net Income-$86.92M-$55.05M$3.18B$249.13M7 Day Performance4.94%4.61%2.90%3.28%1 Month Performance8.03%4.72%3.70%5.55%1 Year Performance-5.99%5.92%36.15%21.12% Aura Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AURAAura Biosciences1.9096 of 5 stars$6.59+2.0%$22.00+233.8%-4.5%$329.76MN/A-3.4750CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180DYNDyne Therapeutics3.5014 of 5 stars$10.16-1.6%$43.93+332.4%-73.5%$1.17BN/A-2.83100AMPHAmphastar Pharmaceuticals4.3742 of 5 stars$24.68+0.5%$32.33+31.0%-39.9%$1.16B$731.97M8.942,028News CoverageNAGENiagen Bioscience1.3647 of 5 stars$13.64+1.5%$19.50+43.0%N/A$1.06B$99.60M80.24120AUPHAurinia Pharmaceuticals3.251 of 5 stars$7.83+0.8%$11.50+46.9%+38.3%$1.05B$235.13M27.96300ELVNEnliven Therapeutics2.5174 of 5 stars$20.29-4.7%$39.60+95.2%-4.1%$1.05BN/A-10.5750Analyst ForecastAnalyst RevisionHigh Trading VolumeABCLAbCellera Biologics2.4886 of 5 stars$3.33-2.3%$8.33+150.3%+40.4%$1.02B$28.83M-5.95500WVEWAVE Life Sciences4.372 of 5 stars$6.96+5.9%$20.50+194.5%+31.0%$1.01B$108.30M-8.29240VERVVerve Therapeutics3.4509 of 5 stars$11.11+0.5%$14.75+32.8%+118.4%$985.92M$32.33M-5.27110High Trading VolumePAHCPhibro Animal Health3.6387 of 5 stars$24.46+2.4%$20.80-15.0%+63.3%$967.94M$1.02B31.361,940 Related Companies and Tools Related Companies Calliditas Therapeutics AB (publ) Competitors Dyne Therapeutics Competitors Amphastar Pharmaceuticals Competitors Niagen Bioscience Competitors Aurinia Pharmaceuticals Competitors Enliven Therapeutics Competitors AbCellera Biologics Competitors WAVE Life Sciences Competitors Verve Therapeutics Competitors Phibro Animal Health Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AURA) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aura Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aura Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AURA Stock Alerts